Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 1/12/2019 6:33:18 PM - Followers: 156 - Board type: Free - Posts Today: 0

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.





Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#7619  Sticky Note https://seekingalpha.com/article/4222803 Lunacy aka John Galt 11/16/18 09:25:53 AM
#7786   Has anybody heard anything on how the search Maciste 01/12/19 06:33:18 PM
#7785   I agree with you completely. ScifiSailor 01/12/19 12:58:32 PM
#7784   Scifi, I like your optimism, and hope your price Lunacy aka John Galt 01/12/19 12:28:35 PM
#7783   90%+ probability? Spot on! ScifiSailor 01/12/19 10:54:43 AM
#7782   Yes Jess, I'm back and loaded for bear. SantaFe Miguel 01/11/19 07:20:47 PM
#7781   Thanks Jess! Hotrodder1 01/11/19 06:00:27 PM
#7780   Santa Fe, were you able to recoup part Jesspro 01/11/19 05:48:38 PM
#7779   Hot rod, Nothing overtly new. It’s a Jesspro 01/11/19 05:43:58 PM
#7778   Ah, got what you meant, thanks. Yes, that Jesspro 01/11/19 05:33:06 PM
#7777   Smart trial design for VOS given that Restasis Lunacy aka John Galt 01/11/19 04:44:38 PM
#7776   Luna, which one are you referring as having Jesspro 01/11/19 04:24:51 PM
#7775   AUPH mentioned in article: www.nasdaq.com/article/9-pharma-stocks-to-watch- somerssalt 01/11/19 12:12:46 PM
#7774   I think there's a 90%+ chance the PR Lunacy aka John Galt 01/11/19 11:03:34 AM
#7773   Lunacy, based on what you know to this Jesspro 01/11/19 09:50:52 AM
#7772   Correct.. biotech_researcher 01/10/19 07:57:14 PM
#7771   I was expecting it within the first half LivingTheDream 01/10/19 05:01:00 PM
#7770   You make it sound like a delay...no delay, Lunacy aka John Galt 01/10/19 04:43:34 PM
#7769   Des got pushed out two more weeks LivingTheDream 01/10/19 04:30:43 PM
#7768   Is there no news from the SF conference yet? Hotrodder1 01/10/19 04:19:58 PM
#7766   Zzaatt, your post had confusing/contradicting words. You may biotech_researcher 01/07/19 12:28:46 PM
#7765   This one we have now is a good zzaatt 01/07/19 10:48:34 AM
#7764   Well, you made money there, all of us Jesspro 01/07/19 09:00:18 AM
#7763   That was a good one Jess.. Thanks for biotech_researcher 01/04/19 08:40:30 PM
#7762   2x Ariad buy price, not BRs $2, just Jesspro 01/04/19 08:07:02 PM
#7761   Yeah, Jess’s math adds 2X to everything ??. biotech_researcher 01/04/19 07:41:01 PM
#7760   Hey Jess, still live in the Bay area. greggors 01/04/19 06:18:12 PM
#7758   3,695,139 shares traded? Up 2 cents!! greggors 01/02/19 04:22:34 PM
#7757   BR, what’s not to like in that article. Jesspro 01/02/19 04:00:12 PM
#7756   True Hottie. To win big, you play big. Jesspro 01/02/19 02:52:22 PM
#7755   On another note; my main holdings are long Hotrodder1 01/02/19 01:33:53 PM
#7754   We all got slaughtered in Ariad! Those that Hotrodder1 01/02/19 01:24:15 PM
#7753   Those concerns are why AUPH didn't hold above Zeppo 01/02/19 11:44:28 AM
#7752   Jess, that article doesn’t make me feel comfortable biotech_researcher 01/02/19 11:23:32 AM
#7751   A recycled article about auph Voclosporin. Don’t get Jesspro 01/02/19 11:18:59 AM
#7750   Congratulations to all the new 2018 AUPH investors. ThePromise247 12/31/18 03:02:28 PM
#7748   I don't even know what to think. It's historyperson 12/28/18 04:52:21 PM
#7747   Oh this is good.. biotech_researcher 12/28/18 04:00:10 PM
#7746   I love days like today! Hotrodder1 12/28/18 02:12:29 PM
#7745   Thank you. Pencow 12/28/18 01:43:51 PM
#7744   Date has not been announced. tiv111 12/28/18 01:35:13 PM
#7743   When is the DES trial data due to Pencow 12/28/18 11:38:07 AM
#7742   My guess is that VOS might actually have Lunacy aka John Galt 12/28/18 11:10:07 AM
#7741   I wish I have that many shares. Jesspro 12/26/18 11:13:30 PM
#7740   I like my 55k shares! Not trading! Hotrodder1 12/26/18 08:11:00 PM
#7739   I will get those 10,000shares back. Unfortunately, I'm SantaFe Miguel 12/26/18 05:39:12 PM
#7738   Thank you. Can you now buy back Maciste 12/26/18 03:14:52 PM
#7737   Santa Fe, thank you. If we may request, Jesspro 12/26/18 03:07:18 PM
#7736   If you're wondering what to attribute this run-up SantaFe Miguel 12/26/18 02:34:50 PM
#7735   Lido, KZR may have a higher cap than Jesspro 12/23/18 07:08:38 PM
#7734   Auph is 2/3 years ahead of KZR. Jesspro 12/23/18 06:42:57 PM